Cargando…
Aging Biomarkers for Clinical Trials and Drug Discovery
Developing targeted therapies first requires a working definition of the condition of interest. Unfortunately for aging, this very initial step poses a challenge since chronological age is often not indicative of biological age nor modifiable. This symposium will demonstrate the enormous progress be...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8679472/ http://dx.doi.org/10.1093/geroni/igab046.014 |
_version_ | 1784616530008342528 |
---|---|
author | Meer, Margarita Sehgal, Raghav Levine, Morgan |
author_facet | Meer, Margarita Sehgal, Raghav Levine, Morgan |
author_sort | Meer, Margarita |
collection | PubMed |
description | Developing targeted therapies first requires a working definition of the condition of interest. Unfortunately for aging, this very initial step poses a challenge since chronological age is often not indicative of biological age nor modifiable. This symposium will demonstrate the enormous progress being made towards developing more reliable and valid measures for quantifying biological aging. First, Dr. Albert T. Higgins Chen will show how inaccuracy caused by noise at individual CpG sites can lead to high technical variability in the most widely applied biomarkers of aging—epigenetic clocks. He will further discuss how this can be overcome through novel statistical techniques. Second, Dr. Benoit Lehallier, will discuss plasma proteomic clocks and share insights into their potential roles in Alzheimer's disease and utilization in clinical trials. Third, quantifying the multifactorial aging process can be facilitated by projects incorporating multimodal biomarker data. Pei-Lun Kuo from the Baltimore Longitudinal Study of Aging will present an analysis of longitudinal trajectories of more than 30 phenotypes, which when combined into a single summarized score yield important insights. Fourth, our ability to uncover aging mechanisms and perform drug screens, requires valid and reliable measures that can be applied in vitro. Christopher Minteer who developed in cellulo epigenetic markers will demonstarte how epigenetic aging changes that can be induced in culture shed light on aging in vivo. Finally, a summarizing discussion will be held by Dr. Morgan Levine, an expert in the field. |
format | Online Article Text |
id | pubmed-8679472 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-86794722021-12-17 Aging Biomarkers for Clinical Trials and Drug Discovery Meer, Margarita Sehgal, Raghav Levine, Morgan Innov Aging Abstracts Developing targeted therapies first requires a working definition of the condition of interest. Unfortunately for aging, this very initial step poses a challenge since chronological age is often not indicative of biological age nor modifiable. This symposium will demonstrate the enormous progress being made towards developing more reliable and valid measures for quantifying biological aging. First, Dr. Albert T. Higgins Chen will show how inaccuracy caused by noise at individual CpG sites can lead to high technical variability in the most widely applied biomarkers of aging—epigenetic clocks. He will further discuss how this can be overcome through novel statistical techniques. Second, Dr. Benoit Lehallier, will discuss plasma proteomic clocks and share insights into their potential roles in Alzheimer's disease and utilization in clinical trials. Third, quantifying the multifactorial aging process can be facilitated by projects incorporating multimodal biomarker data. Pei-Lun Kuo from the Baltimore Longitudinal Study of Aging will present an analysis of longitudinal trajectories of more than 30 phenotypes, which when combined into a single summarized score yield important insights. Fourth, our ability to uncover aging mechanisms and perform drug screens, requires valid and reliable measures that can be applied in vitro. Christopher Minteer who developed in cellulo epigenetic markers will demonstarte how epigenetic aging changes that can be induced in culture shed light on aging in vivo. Finally, a summarizing discussion will be held by Dr. Morgan Levine, an expert in the field. Oxford University Press 2021-12-17 /pmc/articles/PMC8679472/ http://dx.doi.org/10.1093/geroni/igab046.014 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of The Gerontological Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Abstracts Meer, Margarita Sehgal, Raghav Levine, Morgan Aging Biomarkers for Clinical Trials and Drug Discovery |
title | Aging Biomarkers for Clinical Trials and Drug Discovery |
title_full | Aging Biomarkers for Clinical Trials and Drug Discovery |
title_fullStr | Aging Biomarkers for Clinical Trials and Drug Discovery |
title_full_unstemmed | Aging Biomarkers for Clinical Trials and Drug Discovery |
title_short | Aging Biomarkers for Clinical Trials and Drug Discovery |
title_sort | aging biomarkers for clinical trials and drug discovery |
topic | Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8679472/ http://dx.doi.org/10.1093/geroni/igab046.014 |
work_keys_str_mv | AT meermargarita agingbiomarkersforclinicaltrialsanddrugdiscovery AT sehgalraghav agingbiomarkersforclinicaltrialsanddrugdiscovery AT levinemorgan agingbiomarkersforclinicaltrialsanddrugdiscovery |